Literature DB >> 17043120

Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.

Klaudia Kosowska-Shick1, Kathy Smith, Tatiana Bogdanovich, Lois M Ednie, Ronald N Jones, Peter C Appelbaum.   

Abstract

Against 198 viridans group streptococci, 25 Streptococcus bovis strains, and 5 Cardiobacterium hominis strains, MICs of DX-619, a des-F(6)-quinolone, were between 0.004 and 0.25 microg/ml. These MICs were lower than those of other quinolones (< or = 0.008 to > 32 microg/ml). Beta-lactam MICs were between < or = 0.008 and 16 microg/ml. Azithromycin resistance was found in most species, while most were telithromycin susceptible. Glycopeptides and linezolid were active against viridans group strains but inactive against C. hominis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043120      PMCID: PMC1693973          DOI: 10.1128/AAC.01110-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms.

Authors:  K C Kugler; D J Biedenbach; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1999-05       Impact factor: 2.803

2.  In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.

Authors:  Katsuko Fujikawa; Megumi Chiba; Mayumi Tanaka; Kenichi Sato
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.

Authors:  D Molitoris; M-L Väisänen; M Bolaños; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

4.  Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

Authors:  Tatiana Bogdanovich; Duygu Esel; Linda M Kelly; Bülent Bozdogan; Kim Credito; Gengrong Lin; Kathy Smith; Lois M Ednie; Dianne B Hoellman; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis.

Authors:  C Janoir; I Podglajen; M D Kitzis; C Poyart; L Gutmann
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

Review 6.  Viridans-group streptococcal infections in immunocompromised hosts.

Authors:  J L Shenep
Journal:  Int J Antimicrob Agents       Date:  2000-03       Impact factor: 5.283

7.  Prospective national survey of viridans streptococcal bacteraemia risk factors, antibacterial susceptibility and outcome of 120 episodes.

Authors:  M Mrazova; A Docze; E Buckova; L Bucko; M Kacmarikova; E Grey; J Korcova; J Koprnova; Z Saboova; P Beno; M Karvaj; I Svetlansky; A Ondrus; J Benca; M Taziarova; B Rudinsky; V Krcmery
Journal:  Scand J Infect Dis       Date:  2005

8.  Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.

Authors:  J Tankovic; B Perichon; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

9.  High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Authors:  C Janoir; V Zeller; M D Kitzis; N J Moreau; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

10.  Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.

Authors:  N P Brenwald; M J Gill; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more
  1 in total

1.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.